📢 “We found that with the approaches that we used, we were able to achieve about 90% accuracy to classify #rheumatoidarthritis patients starting a new treatment as to whether they were in LDA,” said Dr. Jeffrey Curtis @RADoctor.   https://t.co/AlUwf8J6BU

Did you miss #TheGreatDebate on #ArtificialIntelligence at #ACR25? Join Dr Jinoos Yazdany, @RADoctor and I as we take a whistlestop tour of highlights from the debate, and key points on #AI from convergence. @RheumNow https://t.co/CItSCWszHt

As another #ACR25 Convergence draws to a close, the nontraditional conference badge engendered much discussion. Top picks were Optimistic, Disruptive, and Salty. Which are you? Most fun is when others disagree and pick something else for you. @RheumNow #KnowThyself

In the #ACR25 Great AI Debate, @RADoctor and @JYazdanyMD prepared independently, but in consecutive moments agree (in a very illustrative way): guardrails - they need to happen @RheumNow

In the #ACR25 Great AI debate, @RADoctor shows automated ultrasound scanning - one legitimately promising application ready very soon. I’ve written about this work (ARTHUR/DIANA) for @RheumNow last year - check it out: https://t.co/Zq4ywEjspi

#AI isn’t coming for your job—it’s coming to join your care team. Excited to explore today how AI is reshaping the future of medicine with California’s top #rheumatology providers at @CalRheum. #AI #MedTech #RheumCare

The FDA just completed its first AI-assisted scientific review—marking a historic shift in how new therapies are evaluated. Tasks that took days now take minutes. An AI revolution is underway inside the agency. If this is the start, what’s next? ⚖️🤖💊

US- Top Drug Rx Sales in 2024 Semaglutide $54 Billion Tirzepatide $31.7 B Adalimumab $28B Apixaban $26 B Empagliflozin $20.5 B Pembrolizumab $18 B Ustekinumab $17 B Risankizumab $16 B Dupilumab $15.6 B Etanercept $10.1 B Secukinumab $7.7 B Immune globulin $7.1 B Upadacitinib $7

This week in A&R TMP-SMX significantly reduces risk of serious infections in AAV patients receiving RTX or CYC induction therapy https://t.co/OO2e95uAnv No evidence of increased CV events during 1st 2 years of JAKi use vs TNFi in RA patients https://t.co/qtuPpn21qV

NEW! Can #AI improve how we diagnose, treat, & monitor #rheum patients? In our latest episode, we explore AI’s growing role in #rheum & where it’s taking us next with @RADoctor. Listen HERE → https://t.co/yydtuaY2a4

Great talk at #RNL2025 by Dr Una Makris on managing geriatric rheumatology patients. How often do we under-treat #Rheumatoid arthritis patients with advanced therapies because we fall into the trap of ageism?

Privileged to be at #CSRO discussing how generative and predictive #AI can support #rheumatology in value based care and reimbursement and its potential pitfalls. Fantastic group of people advocating for our field and especially our patients. #VBR #VBC @CSROAdvocacy

RA patients on abatacept have an appalling immunogenic response to Shingrix. Humoral fades away in the first year, and an absence of cellular responses. Alarming and need strategies to combat this #EULAR2024 POS0620 Winthrop/@RADoctor @RheumNow

Great talk by Dr Skip Rizzo alongside many others at #vMed24 describing how to increase the rigor of designing trials of medical extended reality (MXR) interventions in diverse healthcare settings to improve patient outcomes and increase wellness.

Very appreciative to STAR Texas #rheumatology for their kind invitation to discuss new #covid19 and #shingles #vaccine data and how to overcome vaccine hesitancy! Thankful to be included in such an august cadre of speakers this weekend.

Enjoying Casablanca tonight with my sweetheart at the iconic #alabamatheater #ValentinesDay

Dr Ted Mikuls gives a great overview of 20 years of success in the VA RA registry at #ACR2023 deriving insights about #rheumatoid arthritis Rx effectiveness, ILD and more. Wishing him congrats and a happy birthday today.

Find it challenging to communicate risks and benefits of medications to your #rheumatology pts? Following a recent @RheumNow discussion (9/5/23), this new A&R article provides practical guidance using examples from the tofacitinib Oral Surveillance trial.

That’s a wrap! This year’s excellent #epidemiology ISPE conference in Halifax focused on real-world evidence #RWE. Health equity and #AI - enabled patient generated digital health data embedded in Software as a Medical Device (SaMD) featured prominently. #ICPE2023

A recent trial of non-invasive, auricular vagus nerve stimulation (VNS) to treat #RheumatoidArthritis failed, but that shouldn't diminish enthusiasm for implantable VNS that may benefit RA, #IBD, or other autoimmune diseases, currently in Phase 3 trials.